There’s a new drug to treat Alzheimer’s disease, but those who might benefit from it know almost nothing about it, a new study shows.
In spring 2021, for the first time in decades, the U.S. Food and Drug Administration approved a drug to treat Alzheimer’s disease. Enthusiasm for the drug, aducanumab, was swiftly eclipsed by concerns about efficacy, prohibitive cost and serious side effects.
Now, USC researchers have found older Americans most at risk for Alzheimer’s know little about aducanumab (brand name Aduhelm), despite the fact that an overwhelming majority of survey respondents said they were worried about Alzheimer’s…
